Literature DB >> 8157685

Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression.

G Y Wu1, P Zhan, L L Sze, A R Rosenberg, C H Wu.   

Abstract

Adenovirus type 5 was modified by coupling an asialoglycoprotein-polylysine conjugate to the virus by reactions that activate carbohydrate residues. Wild-type virus modified in this manner had greatly decreased infectivity toward normally susceptible HeLa S3 (asialoglycoprotein receptor (-)) and SK Hep1 (asialoglycoprotein receptor (-)) cells leaving 91 and 86% viable, respectively, after 48 h. However, with Huh 7 (asialoglycoprotein receptor (+)) cells, modified virus retained its infectivity leaving only 19% of cells viable under identical conditions. Modified virus was complexed to DNA in the form of a plasmid, pSVHBV surf, containing the gene for hepatitis B surface antigen as a marker of gene expression. Huh 7, receptor (+), cells treated with modified wild type, and modified replication-defective d1312 virus complexed to DNA raised antigen levels by approximately 13- and 30-fold, respectively, compared with asialoglycoprotein-polylysine DNA complex alone. Competition with a large excess of an asialoglycoprotein blocked the enhancement by more than 95%. Using a beta-galactosidase marker gene, the number of cells transfected by modified virus was found to be 200-fold higher than complex alone. Yet, specificity was retained exclusively for asialoglycoprotein receptor-bearing cells. These data indicate that adenovirus can be chemically modified by coupling ligands resulting in targeted gene expression dictated specifically by receptor recognition of the attached ligand.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157685

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  A DNA delivery system containing listeriolysin O results in enhanced hepatocyte-directed gene expression.

Authors:  Cherie M Walton; Catherine H Wu; George Y Wu
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

2.  Site-specific gene delivery in vivo through engineered Sendai viral envelopes.

Authors:  K Ramani; Q Hassan; B Venkaiah; S E Hasnain; D P Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

Review 3.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 4.  Pharmaceutical approach to somatic gene therapy.

Authors:  F D Ledley
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter.

Authors:  C Ebbinghaus; A Al-Jaibaji; E Operschall; A Schöffel; I Peter; U F Greber; S Hemmi
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers.

Authors:  H C Chiou; M V Tangco; S M Levine; D Robertson; K Kormis; C H Wu; G Y Wu
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

7.  Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 8.  Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity.

Authors:  Dirk Roggenbuck; Maria G Mytilinaiou; Sergey V Lapin; Dirk Reinhold; Karsten Conrad
Journal:  Auto Immun Highlights       Date:  2012-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.